UPB - Upstream Bio Corp P/S Multiple
The price-to-sales ratio reflects the market valuation of the asset, with the 54.40 level serving as a critical benchmark. The progress of Upstream Bio Inc (UPB) depends on test results, regulatory verdicts, and investment inflows. While the company is building a patent-protected targeted therapy ecosystem, its focus on a single drug for respiratory pathologies creates significant binary risks for investors.
Metric breakdowns and analytics for Upstream Bio Corp (UPB)
- current quotes and average value forecast:
- market capitalization statistics:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Capital Upstream Bio Inc|UPB - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Upstream Pharma|UPB - Company Aggregate Debts|Debts to Book Value Upstream Bio Corp|UPB - Company Long-Term Debts|Company Short-Term Debts Upstream Bio|Quick Liquidity Indicator upstreambio.com
- earnings and valuation multiples indicators:
UPB - Net Income|Expected Net Income Upstream Bio Inc|UPB - P/E Multiple|Future Price to Earnings Upstream Bio, Inc.|UPB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Upstream Bio Corp|UPB - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Upstream Bio|UPB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months upstreambio.com|UPB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Upstream Bio Inc
- total revenue and sales volume data:
General company analysis:UPB - upstreambio.com
The P/S ratio determines the market value of a business relative to its annual sales volume, allowing an investor to assess the degree of overpayment for an asset in an environment of expensive capital. For Upstream Bio Inc (UPB), where efficiency depends on the complexity of cold-chain logistics for biomaterials, the P/S time series on GURU.Markets reflects market confidence in the scalability of this infrastructure and the potential for future revenues.
Competing companies
ARGX - Price to Sales|BioNTech - Market Cap to Revenue|P/S Multiple Abivax Pharma ABVX|ADMA - Price-to-Revenue Ratio|Price-to-Sales Ratio PTGX|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|KNSA - Price-to-Revenue Coefficient|Market Cap to Revenue GRFS|ADPT (Adaptive Biotech) - Market Cap to Sales Volume|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|veratx.com (VERA) - Price to Sales|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS - P/S Multiple|AbCellera Biologics Inc (ABCL) - Price-to-Revenue Ratio|Market Cap to Revenue Tourmaline|Market Cap to Revenue PGEN|PHAR: Market Capitalization-to-Revenue Ratio|P/S Multiple NKTR|Price-to-Revenue Ratio ZBIO (Zenas Bio)|P/S Multiple IMNM (Immunome Corp)|Price-to-Revenue Coefficient Gossamer Bio Corp. (GOSS)|KALV - Price-to-Revenue Ratio|Price to Sales septerna.com|PVLA (Pieris Pharmaceuticals, Inc.) - Market Cap to Revenue|Savara Inc - Market Capitalization-to-Revenue Ratio|RIGL (Rigel Pharmaceuticals Inc) - P/S Multiple|AnaptysBio Inc. (ANAB) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|engene.com - Market Cap to Revenue Ratio|P/S Multiple RAPT (RAPT Therapeutics)|JBIO - Market Cap to Revenue|ACRS: Market Cap to Revenue|KYTX - P/S Multiple|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Price-to-Sales Ratio CABA (cabalettabio.com)|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|Price-to-Revenue Ratio THTX|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|ELDN: Price-to-Sales Ratio|P/S Multiple AGEN (Agenus)|Market Capitalization-to-Revenue Ratio CLYM|Zura Bio - P/S Multiple|ATYR - P/S Multiple|adagene.com (ADAG) - Price-to-Revenue Ratio|Ikena Oncology - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Shattuck Labs Inc|Market Cap to Revenue Equillium Bio (EQ)|P/S Multiple CNTB|P/S Multiple immunic-therapeutics.com (IMUX)|Atara Bio - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IFRX|X4 Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient Adicet Bio ACET|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|Market Cap to Revenue SABS (SAB Biotherapeutics)|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB: Market Cap to Revenue Ratio|GeoVax Labs Inc - P/S Multiple|Price to Sales Edesa Biotech Corp|IBIO (iBio, Inc.) - Market Cap to Revenue|Carisma Therapeutics Inc. (CARM) - P/S Multiple|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Bolt Bio - Price-to-Sales Ratio|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Price-to-Revenue Coefficient aptevotherapeutics.com|AIM ImmunoTech Inc. - Market Cap to Revenue|Market Cap to Sales Volume ADTX (Aditxt Inc.)|GRI - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio XRTX (XORTX Therapeutics Inc)|HIND: P/S Multiple|Price to Sales Revelation Biosciences Corp (REVB)|INDP (Indaptus Therapeutics) - P/S Multiple|P/S Multiple scinai.com|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|Market Cap to Revenue affimed.com AFMD|Allakos - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio HOOK|IGM Bio - P/S Multiple|ITOS: Price-to-Revenue Ratio|OCEA: P/S Multiple|TCBP - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Third Harmonic Bio, Inc
